These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31087053)

  • 41. The therapeutic use of a new potassium-sparing diuretic, amiloride, and a converting enzyme inhibitor, MK-421, in preventing hypokalemia associated with primary and secondary hyperaldosteronism.
    Griffing GT; Melby JC
    Clin Exp Hypertens A; 1983; 5(6):779-801. PubMed ID: 6309436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
    Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
    Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The diurnal rhythm of plasma aldosterone, plasma renin activity, plasma cortisol and serum growth hormone and subnormal responsiveness of aldosterone to angiotensin-II in the patients with normotensive acromegaly.
    Ichikawa S; Sakamaki T; Tonooka S; Sugai Y
    Endocrinol Jpn; 1976 Feb; 23(1):75-82. PubMed ID: 945156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension.
    Cerasola G; Cottone S; D'Ignoto G; Grasso L; Carone MB; Carapelle E; Contorno A
    Clin Ther; 1987; 9(4):390-9. PubMed ID: 3038326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new family with dexamethasone-suppressible hyperaldosteronism: aldosterone unresponsiveness to angiotensin II.
    Fallo F; Sonino N; Armanini D; Luzzi T; Pedini F; Pasini C; Mantero F
    Clin Endocrinol (Oxf); 1985 Jun; 22(6):777-85. PubMed ID: 2990765
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe hyperaldosteronism in neonatal Task3 potassium channel knockout mice is associated with activation of the intraadrenal renin-angiotensin system.
    Bandulik S; Tauber P; Penton D; Schweda F; Tegtmeier I; Sterner C; Lalli E; Lesage F; Hartmann M; Barhanin J; Warth R
    Endocrinology; 2013 Aug; 154(8):2712-22. PubMed ID: 23698720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of angiotensin I converting enzyme inhibitor (SQ 14,225) on the responses of blood pressure and steroid hormone to angiotensin II and ACTH infusion in hypertensive subjects.
    Ueda Y; Honda M; Hatano M
    Jpn Circ J; 1982 Mar; 46(3):267-73. PubMed ID: 6278173
    [TBL] [Abstract][Full Text] [Related]  

  • 49. mTORC1 Signaling Contributes to Drinking But Not Blood Pressure Responses to Brain Angiotensin II.
    Muta K; Morgan DA; Grobe JL; Sigmund CD; Rahmouni K
    Endocrinology; 2016 Aug; 157(8):3140-8. PubMed ID: 27254006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma.
    Lin YH; Lin LY; Chen A; Wu XM; Lee JK; Su TC; Wu VC; Chueh SC; Lin WC; Lo MT; Wang PC; Ho YL; Wu KD;
    Atherosclerosis; 2012 Mar; 221(1):154-9. PubMed ID: 22197109
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tp-e interval, Tp-e/QT and Tp-e/QTc ratio in hypertensive patients with primary aldosteronism.
    Demirtas D; Sumbul HE; Bulut A; Demirtas AO; Gulumsek E; Koca H; Icen YK; Koc M
    Clin Exp Hypertens; 2020; 42(1):93-98. PubMed ID: 31204516
    [No Abstract]   [Full Text] [Related]  

  • 52. Long-term re-evaluation of primary aldosteronism after medical treatment reveals high proportion of normal mineralocorticoid secretion.
    Lucatello B; Benso A; Tabaro I; Capello E; Caprino MP; Marafetti L; Rossato D; Oleandri SE; Ghigo E; Maccario M
    Eur J Endocrinol; 2013 Apr; 168(4):525-32. PubMed ID: 23321497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism.
    Hashimura H; Shen J; Fuller PJ; Chee NYN; Doery JCG; Chong W; Choy KW; Gwini S; Yang J
    Clin Endocrinol (Oxf); 2018 Sep; 89(3):308-313. PubMed ID: 29873811
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of saralasin, an angiotensin II antagonist, on blood pressure and the renin-angiotensin-aldosterone system in normal and hypertensive subjects.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):48-52. PubMed ID: 1071403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prenatal Mechanistic Target of Rapamycin Complex 1 (m TORC1) Inhibition by Rapamycin Treatment of Pregnant Mice Causes Intrauterine Growth Restriction and Alters Postnatal Cardiac Growth, Morphology, and Function.
    Hennig M; Fiedler S; Jux C; Thierfelder L; Drenckhahn JD
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28778941
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism.
    Wisgerhof M; Brown RD; Hogan MJ; Carpenter PC; Edis AJ
    J Clin Endocrinol Metab; 1981 Feb; 52(2):195-8. PubMed ID: 7462385
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives.
    Rossi E; Regolisti G; Negro A; Sani C; Davoli S; Perazzoli F
    Am J Hypertens; 2002 Oct; 15(10 Pt 1):896-902. PubMed ID: 12372677
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nocturnal, daytime, and postural changes of plasma aldosterone before and during dexamethasone in adenomatous and idiopathic aldosteronism.
    Hoefnagels WH; Drayer JI; Smals AG; Benraad TJ; Kloppenborg PW
    J Clin Endocrinol Metab; 1980 Dec; 51(6):1330-4. PubMed ID: 7440698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test.
    Fogari R; Preti P; Zoppi A; Rinaldi A; Fogari E; Mugellini A
    Hypertens Res; 2007 Feb; 30(2):111-7. PubMed ID: 17460380
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
    Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
    J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.